After Anthropic's Bell-Ringing Debut, Which Public Companies Are Being Reshaped by AI Models? - Odaily

Anthropic IPOImpact on Public CompaniesAI Large ModelsCybersecurityCompute Chips
1 hour agoSource: blockweeks.com
After Anthropic's Bell-Ringing Debut, Which Public Companies Are Being Reshaped by AI Models? - Odaily


Original | Odaily Planet Daily (@OdailyChina)

Author | Wenser (@wenser 2010 )Anthropic 敲钟后,哪些上市公司被 AI 大模型改写? - Odaily

On the evening of November 19, the "largest IPO in history" Anthropic officially closed its listing, with its fully diluted market capitalization once reaching as high as $1.8 trillion during trading, placing it among the "Top 10 companies by market capitalization globally."

Before the bell-ringing ceremony, Anthropic co-founder Dario once again discussed topics such as the evolution of AI model capabilities, safety slowdowns, and computing power and cash investment. He also mentioned that "AI-human collaboration is expected to compress a century of scientific and medical progress into 10 years," and in the "Founder's Open Letter" promised that Claude will never integrate advertising.

Overall, Dario outlined a macro vision in which "humanity's future rests on AI alone"; but behind this narrative, he also planted the seeds for multiple sectors that may come under pressure. Of course, as AI accelerates its progress, tech giants and medical giants are also rapidly evolving in their own ways. With AI as a powerful booster, their future direction remains unknown.

The Many Faces Behind Anthropic's IPO: Security, Healthcare, and Chips

The reason Anthropic's IPO was pushed forward so quickly and urgently is that, despite having already reached Series H in previous financing, the company still faces rising computing power expenditures and cybersecurity offense and defense that it has no choice but to undertake. These two are also the two major sectors that will be directly affected after its IPO. Healthcare is one of the main targets of Dario's "facing challenges head-on" and "painting a big picture." Let's look at them one by one below.

Impact One: Positive for Cybersecurity Stocks, Negative for Software Stocks

First, the cybersecurity sector. Although with the development of AI large models, we have entered a great era of "AI security offense and defense for all," for cybersecurity companies this cannot be regarded as an entirely bad thing. After all, on the one hand, it means "more business"; on the other hand, AI large models are also helping cybersecurity companies achieve goals such as efficiently screening vulnerabilities and promptly fixing bugs.

In this regard, for Nasdaq-listed company Palo Alto Networks (PANW), this is an industry-level positive. Dario has previously listed cyberattacks multiple times as the most realistic dual-use risk, and the "Founder's Open Letter" also mentioned the Project Glasswing defense initiative launched in April this year, with PANW as one of the first core partners. Public information disclosure shows that in May this year, PANW used frontier models such as Anthropic's Claude Mythos, Claude Opus 4.7, and OpenAI's GPT-5.5-Cyber to scan more than 130 products in about one month and found 75 valid vulnerabilities, far higher than the company's usual disclosure frequency of 5 to 10 per month. Internal testing shows that frontier models achieved a success rate of over 70% in chaining multiple minor issues into usable attack paths, but this was also accompanied by a false positive rate of about 30%, and security teams still need to invest substantial engineering effort to build dedicated scanning guardrails. Another security company founded in 2011, CrowdStrike (CRWD), is in a similar situation, with its stock price rising as much as 49.79% over the past 6 months. Although the performance of such companies is also a main reason for the stock price increase, the development of AI large models has indeed played a boosting role to some extent.

In sharp contrast are software stocks.

In the enterprise SaaS software sector, Salesforce (NYSE: CRM). Although the "Salesforce Case Study" simultaneously released on Anthropic's IPO official website shows that the company's engineering team, with the assistance of Claude models, increased per-capita effective output by 151% year-on-year and reduced online incident rates by 5%; and the two sides have also carried out product-level cooperation configurations, and Salesforce also holds less than 1% of Anthropic's equity, Anthropic still poses a certain threat to it, and Salesforce has fallen as much as 24.39% in the past month.

Anthropic 敲钟后,哪些上市公司被 AI 大模型改写? - Odaily

The capital market is still repeatedly weighing which side carries more weight: cost reduction and efficiency improvement, or seat discounting. A similar timing mismatch also occurred with IT consulting and systems integration giant Accenture (ACN). Although Anthropic's prospectus and roadshow video listed Accenture as an important customer and integration partner, and Accenture CEO Julie Sweet revealed that in the short term, large government and enterprise demand for large model integration and compliance will bring Accenture a new wave of systems integration and data governance orders, whether it can ensure the long-term validity of orders and the continued existence of its ecological niche is still unknown.

Impact Two: Healthcare, National Defense Security, and Computing Power Chips

On the bell-ringing stage, Dario painted a very big picture, but also left Anthropic a way out in advance. The gist of his original words was, "AI large models are expected to compress a century of medical progress into ten years." This is only a long-term vision; at the current stage, it is still in the early results phase, and medical experiments and clinical trials still require a certain amount of time.

Among specific cases in this regard, medical giants are the most notable.

Among specific pharmaceutical companies, Eli Lilly (LLY) has relatively more solid implementation. According to the "Eli Lilly Case Study" officially released by Anthropic, since accessing Claude in 2024, in April this year the company became one of the first large pharmaceutical companies to open Claude Enterprise to more than 50,000 employees, with full-time employee activity exceeding 85% across five major functions: legal compliance, technology, finance, oncology, and R&D in October 2026, it also launched a pilot of the Claude Science research workbench and jointly refined data leak prevention audit hooks. The related cooperation has greatly accelerated early target literature retrieval and R&D collaboration, but new drugs usually take more than 3 to 5 years from project initiation to approval. In the short term, the stock prices of large pharmaceutical companies still depend heavily on the sales ramp-up pace of blockbuster drugs and medical insurance policies.

Another large pharmaceutical company, Bristol Myers Squibb (BMY), has taken bigger steps. Previously, BMY executive Greg Meyers introduced that they had compressed real-world evidence (RWE) analysis that originally took one to two months into 4 to 5 minutes, and expected AI to shorten the overall duration of clinical trials by 20% to 30%. Of course, limited by factors such as patient recruitment speed, hospital ethics approval, and FDA review, the current 20% to 30% reduction remains an internal company expectation and has not yet been realized in complete large-sample Phase III pipelines.

Clinical trial outsourcing leader IQVIA (IQV) is no less impressive. The company previously claimed that with tools such as AI large models it had achieved results including 33% faster study start-up, 50% faster data cleaning, and more than 45% shorter intervals between trial stages, which can help pharmaceutical companies bring new drugs to market up to 2 years earlier. Going forward, if IQVIA, which possesses proprietary clinical databases, compliance experience, and about 94,000 employees, can upgrade its data platform and high-value-added agency services, it is expected to usher in further rapid growth.

In terms of national defense security, Palantir Technologies (PLTR) is a key company involved. Previously, Palantir CTO Shyam Sankar publicly emphasized that the U.S. Pentagon had already replaced Claude with xAI, OpenAI, Google, and Nvidia's open-source model Nemotron in the Maven intelligent system, and that missions were unaffected; in subsequent interviews he also emphasized that the company would strengthen customers' ability to securely switch between different AI models. At present, it is not that PLTR needs Anthropic, but that Anthropic needs to manage its relationship with PLTR and the U.S. Department of Defense.

Of course, if Anthropic subsequently expands the scope of directly delivering end-to-end AI agents to federal and subordinate departments, PLTR will also be affected to some extent, but its stock price trend will still mainly depend on U.S. national defense security spending and market sentiment toward the AI sector.

Anthropic 敲钟后,哪些上市公司被 AI 大模型改写? - Odaily

Finally, let's talk about the targets related to computing power chips.

After vaguely participating in the storm surrounding Nvidia founder Jensen Huang's departure, Anthropic claimed that it could "get models running on AMD chips in 3 days." Combined with AMD's impressive financial results, this once drove its stock price to rise against the trend within the semiconductor sector.

Anthropic's roadshow materials and fact sheet also list AMD GPUs alongside Amazon Trainium, Google TPU, and Nvidia GPUs as the four core computing power architectures; but according to AI Daily Radar's verification against the prospectus, the 3-day result only covers prompt processing for a single model, and does not include the much more difficult large-scale cluster training, and it is only data disclosed unilaterally by Anthropic, with no third-party independent benchmark retest seen to date.

Yesterday, short-selling firm Hunterbrook Media even published a report accusing AMD products of suspected violations of export controls and other issues, triggering a sharp drop in its stock price. In the short term, Anthropic's listing is still a positive for AMD, but subsequent order verification is still needed to confirm whether its stock price can receive long-term support.

But regardless, change has already occurred, and the butterfly effect triggered by Anthropic's IPO will continue to spread in the coming years. As for its future growth direction, whether it is the "Leviathan of the AI field" or the "sword-bearer of the AI industry," that will depend on where company executives, including Dario, go from here.



Source link